Board of Directors

Susannah Gray Former Executive Vice President, Finance & Strategy, Royalty Pharma Management

Susannah Gray brings more than 30 years of biopharmaceutical experience specifically in corporate finance and capital markets roles, most recently serving as EVP, Finance & Strategy of Royalty Pharma Management, LLC. Ms. Gray spent 14 years as Executive Vice President and Chief Financial Officer of Royalty Pharma before retiring in 2019 just ahead of the Company’s initial public offering. At Royalty Pharma, Ms. Gray led the Company’s efforts to maximize its financial capabilities. In her career at Royalty Pharma, she increased the debt facilities from approximately $200 million to $7 billion, and was responsible for over $20 billion in total financing. She also raised $2.0 billion equity capital for the Company.

Prior to joining Royalty Pharma, Ms. Gray had a 14-year career in investment banking. In her most recent role, she was a Managing Director and the Senior Analyst covering the healthcare sector for CIBC World Market’s high yield group from 2002 to 2004. She worked in a similar capacity at Merrill Lynch prior to joining CIBC World Markets. Ms. Gray joined Merrill Lynch in April 1999 after nine years at Chase Securities (a predecessor of JP Morgan), working in various capacities within the high yield and the structured finance groups. Ms. Gray received a BA with honors from Wesleyan University and holds an MBA degree from Columbia University. Ms. Gray currently serves on the board of directors of Susan G. Komen and is on the board of trustees at Wesleyan University.

Dave Johnson Former Founder and Chief Executive Officer, VelosBio

Most recently Dave Johnson was CEO of VelosBio. Velos, an oncology- focused clinical stage biopharmaceutical company, focused on novel antibody drug conjugates (ADCs) and bispecific antibodies (BiAbs) targeting the oncofetal antigen ROR1 utilizing technology licensed from Tom Kipps, MD PhD and UC San Diego. Mr. Johnson founded Velos in 2017, built a world-class leadership team, and raised approximately $200M in capital from a top-tier syndicate of life science investors to advance the company’s programs. Under his leadership the company filed an IND for its lead ROR1-directed ADC VLS-101 in Q4 2018, started enrolling patients in the Phase 1 first-in-human clinical trial in Q1 2019 and in Q4 2020 was acquired by Merck for $2.75B.

Prior to VelosBio, Mr. Johnson was CEO at Acerta Pharma, where he led the company through a critical phase of growth from approximately 40 to 150+ employees and from a signal-seeking first-in-human trial for acalabrutinib to more than 20 active clinical studies. Mr. Johnson’s tenure included the regulatory negotiation and launch of three registration-directed trials, including two global Phase 3 trials for acalabrutinib, and culminated in the execution of a strategic transaction with AstraZeneca valued at up to $7B. Mr. Johnson’s early experience spans from pre-clinical development to all phases of clinical development through product launch. He has extensive experience in fundraising and deal making and has made significant contributions to drugs ultimately garnering NDA/sNDA approval including acalabrutinib, idelalisib, romidepsin, and bortezomib. Mr. Johnson is a co-author on numerous publications and holds a bachelor’s degree from Indiana University.

Karen McGinnis Former Vice President and Chief Accounting Officer, Illumina

Karen McGinnis has served as a member of the Board of Directors since March 2021. Ms. McGinnis has over 30 years of experience in executive operational and finance roles at international public companies. She most recently served as Vice President & Chief Accounting Officer of Illumina, Inc., a leader in sequencing- and array-based solutions for genetic and genomic analysis from November 2017 until her retirement on April 2, 2021. Prior to joining Illumina, Ms. McGinnis served from February 2016 to April 2017 as Director, President and Chief Executive Officer of Mad Catz Interactive, Inc. a global provider of innovative interactive entertainment products. From June 2013 through February 2016, Ms. McGinnis served as Mad Catz’ Chief Financial Officer. Prior to joining Mad Catz, Ms. McGinnis served from November 2009 through May 2013 as Chief Accounting Officer of Cymer, Inc., the world’s leading supplier of light sources used in the photolithography process for semiconductor or chip manufacturing until its acquisition in 2013. Ms. McGinnis also served as Chief Accounting Officer for Insight Enterprises, Inc., from September 2006 until March 2009, its Senior Vice President of Finance from 2001 through September 2006 and its Vice President of Finance from 2000 through 2001. Ms. McGinnis also serves as a director of Alphatec Holdings, Inc. (Nasdaq: ATEC) and Absci Corporation (Nasdaq: ABSI). Ms. McGinnis is a Certified Public Accountant and earned her BBA in Accounting from the University of Oklahoma.

Board Observers